Pfizer’s abrocitinib receives positive CHMP opinion for the treatment of adults with moderate to severe atopic dermatitis

Pfizer

15 October 2021 - CHMP also recommends Xeljanz (tofacitinib) approval for the treatment of adults with active ankylosing spondylitis

Pfizer today announced that the EMA's CHMP has adopted a positive opinion recommending the 100 mg and 200 mg doses of abrocitinib, an oral, once daily, Janus kinase 1 inhibitor, for marketing authorisation to treat moderate to severe atopic dermatitis in adults who are candidates for systemic therapy. 

Read Pfizer press release

Michael Wonder

Posted by:

Michael Wonder